Applied DNA Sciences announces restructuring, 27% workforce reduction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Company Restructuring: Applied DNA Sciences is restructuring to focus on its synthetic DNA manufacturing business, LineaRx, resulting in a 27% workforce reduction and the cessation of operations at Applied DNA Clinical Labs effective June 27, 2025.
Financial Impact: The restructuring aims to reduce operating costs significantly, with an expected 23% decrease in annual payroll costs, despite incurring one-time charges related to the workforce reduction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
